Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27049138 | 0.82 | CTSD (0.40) | CTSDCRBNTSHR | |
| SCHEMBL13074412 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL14005348 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL16350668 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL12809719 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL13399686 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL13424753 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL1226598 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL16316014 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP | |
| SCHEMBL764361 | 0.74 | TSHR (0.58) | CRBNTSHRBRPF1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291063-A1 | PROTEASE INHIBITION | KINGS COLLEGE LONDON (GB) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291063-A1 | PROTEASE INHIBITION | ADAM17, ADAM33, ADAM8 | CTSD 140/4885CRBN 1525/4885TSHR 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.